Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 18, 2021 - The FDA announced the approval of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), as the first interchangeable biosimilar to AbbVie’s Humira® (adalimumab).
Return to publications